Dyslipidemia management in patients with the first acute coronary event: A real world study based on electronic medical records
- Conditions
- Health Condition 1: E785- Hyperlipidemia, unspecified
- Registration Number
- CTRI/2022/07/043875
- Lead Sponsor
- Dr Reddys Laboratories Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1 Electronic medical data of Patients with a confirmed diagnosis (either by angiography or clinical findings) of the first ACS event (STEMI [ST elevation myocardial infarction]/NSTEMI [non-ST elevation myocardial infarction]/ unstable angina)
2 Minimum of 12 months of follow-up data post statin therapy initiation
3 Patients initiated statin therapy prior to or post first ACS event
4 Patients considered for initiation/ maintenance/ modification of statin therapy before discharge from hospital
EMR of Patients with a history of hospital admission for ACS in the past 12 months before the index event , type 1 diabetes mellitus, history of malignancy, patients with active or suspected or with history of hepatic or stage 5 renal disease, history of uncontrolled hypothyroidism, alcohol, or drug abuse, Patients on hormone replacement therapy or oral contraceptives within 3 months of enrollment or pregnant patient
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 The dose of statin/statin plus other lipid-lowering therapies after the first ACS event <br/ ><br>at discharge and the end of 12 months <br/ ><br> <br/ ><br>2 The proportion of patients with a history of dyslipidemia and first ACS event and <br/ ><br>the dose of statins/statin plus other lipid-lowering therapies during/before the <br/ ><br>event, at discharge and the end of 12 monthsTimepoint: Baseline and 12 months
- Secondary Outcome Measures
Name Time Method 1 percentage of patients with co-morbid conditions and risk factors stratified by age and sex <br/ ><br> <br/ ><br>2 Utilization pattern of statin/statin plus other lipid-lowering therapy in dyslipidemia <br/ ><br>patients with first ACS event and having comorbidities <br/ ><br> <br/ ><br>3 Incidence rates of recurrent ACS, stroke, heart failure, <br/ ><br>revascularization, and cardiovascular-specific deaths reportedTimepoint: Baseline or discharge from hospital and end of 12 months